Recently, under the guidance of the Guangzhou Municipal Science and Technology Bureau, the “2025 Discovering Guangzhou Unicorn Innovative Enterprises” list, organized by the Guangzhou Science and Technology Innovation Enterprise Association and co-initiated by institutions including the Guangzhou Industrial Development Research Institute, was officially announced. Following a rigorous selection process, Guangzhou Canton Biologics Technology Co., Ltd. was successfully selected for the 2025 Guangzhou “Future Unicorn” Innovative Enterprise List, owing to its outstanding technological innovation capabilities and high growth potential in the biopharmaceutical CDMO sector.

The “Discovering Guangzhou Unicorn” initiative aims to identify and cultivate a group of outstanding enterprises with strong innovation, rapid growth, and significant development potential. It serves as an important barometer for observing Guangzhou’s new economic development and future industry directions. “Future Unicorn” enterprises, as the representatives with the greatest growth potential, are regarded as pioneering forces in breaking through new technologies, opening up new tracks, and leading new industries.

This selection represents high recognition from government and industry authorities of Canton Biologics’ comprehensive strength as an international biologics CDMO company. Since its establishment, Canton Biologics has consistently been driven by its core proprietary technologies, building a full-chain one-stop service platform covering cell line development, process development, GMP production, and quality analysis, dedicated to accelerating and empowering global biopharmaceutical innovators.

This honor is an affirmation of our past commitment and a motivation for our future journey. Canton Biologics will take this as a new starting point to continue deepening its presence in the cutting-edge biopharmaceutical field, strengthening technological innovation and global expansion, and with higher standards and better services, help more innovative drugs transition from the laboratory to clinical use and to the market, contributing the strength of a “Future Unicorn” to the development of the biopharmaceutical industry in Guangzhou and globally.